Stocks and Investing
Stocks and Investing
Fri, July 23, 2021
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Geulah Livshits Maintained (ADVM) at Hold with Decreased Target to $30 on, Jul 23rd, 2021
Geulah Livshits of Chardan Capital, Maintained "Adverum Biotechnologies, Inc." (ADVM) at Hold with Decreased Target from $50 to $30 on, Jul 23rd, 2021.
Geulah has made no other calls on ADVM in the last 4 months.
There are 3 other peers that have a rating on ADVM. Out of the 3 peers that are also analyzing ADVM, all agree with Geulah's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Gbola Amusa of "Chardan Capital" Downgraded from Strong Buy to Hold and Decreased Target to $50 on, Thursday, April 29th, 2021
- Joon Lee of "Truist Securities" Downgraded from Strong Buy to Hold and Decreased Target to $90 on, Thursday, April 29th, 2021
- Luca Issi of "RBC Capital" Downgraded from Buy to Hold and Held Target at $60 on, Thursday, April 29th, 2021
Contributing Sources